Keymed Biosciences Inc., a China-based biopharmaceutical company (HKG: 2162), has announced a significant licensing agreement with UK-based Platina Medicines Ltd (PML). The agreement grants Platina Medicines exclusive global development, manufacturing, and commercialization rights to Keymed’s CM336, excluding mainland China, Hong Kong, Macau, and Taiwan.
Financial Terms and Considerations
Under the terms of the deal, Keymed Bio will receive an upfront payment of USD 16 million and near-term payments. Additionally, Keymed Bio will acquire a minority stake in Ouro Medicines, LLC, the parent company of PML, as part of the consideration. The company is also eligible for up to USD 610 million in additional payments and tiered royalties based on net sales, highlighting the potential value of CM336 in the global market.
CM336: A Promising Bispecific Antibody for Multiple Myeloma
CM336 is an in-house developed bispecific antibody (BsAb) targeting BCMA and CD3, which is currently undergoing a multi-center, open Phase I/II clinical study for the treatment of recurrent or refractory multiple myeloma. This innovative therapy has the potential to transform the treatment landscape for patients suffering from multiple myeloma, a cancer that affects plasma cells in the bone marrow.-Fineline Info & Tech
Leave a Reply